153 related articles for article (PubMed ID: 8698749)
1. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.
Reles A; Schmider A; Press MF; Schönborn I; Friedmann W; Huber-Schumacher S; Strohmeyer T; Lichtenegger W
J Cancer Res Clin Oncol; 1996; 122(8):489-94. PubMed ID: 8698749
[TBL] [Abstract][Full Text] [Related]
2. [Overexpression of p53 protein in ovarian carcinomas: correlation with histopathologic data and clinical course].
Reles A; Press MF; Schönborn I; Lichtenegger W; Strohmeyer T
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():93-7. PubMed ID: 8672936
[TBL] [Abstract][Full Text] [Related]
3. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma.
Klemi PJ; Pylkkänen L; Kiilholma P; Kurvinen K; Joensuu H
Cancer; 1995 Oct; 76(7):1201-8. PubMed ID: 8630898
[TBL] [Abstract][Full Text] [Related]
4. Quantification of p53 in epithelial ovarian cancer.
Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
[TBL] [Abstract][Full Text] [Related]
5. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.
Levesque MA; Katsaros D; Yu H; Zola P; Sismondi P; Giardina G; Diamandis EP
Cancer; 1995 Mar; 75(6):1327-38. PubMed ID: 7882283
[TBL] [Abstract][Full Text] [Related]
6. p53 expression in ovarian borderline tumors and stage I carcinomas.
Kupryjańczyk J; Bell DA; Yandell DW; Scully RE; Thor AD
Am J Clin Pathol; 1994 Nov; 102(5):671-6. PubMed ID: 7942635
[TBL] [Abstract][Full Text] [Related]
7. [Expression P53 protein and chromosome aberrations in benign tumors and ovarian carcinoma].
Kamiński K; Putowski L; Oleszczuk J
Ginekol Pol; 2003 Sep; 74(9):741-5. PubMed ID: 14674118
[TBL] [Abstract][Full Text] [Related]
8. Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas.
van der Zee AG; Hollema H; Suurmeijer AJ; Krans M; Sluiter WJ; Willemse PH; Aalders JG; de Vries EG
J Clin Oncol; 1995 Jan; 13(1):70-8. PubMed ID: 7799045
[TBL] [Abstract][Full Text] [Related]
9. p53 accumulation in ovarian carcinomas and its prognostic implications.
Bosari S; Viale G; Radaelli U; Bossi P; Bonoldi E; Coggi G
Hum Pathol; 1993 Nov; 24(11):1175-9. PubMed ID: 8244317
[TBL] [Abstract][Full Text] [Related]
10. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
13. [P53-status in primary ovarian carcinomas, ovarian metastases of neoplasms in other sites and benign ovarian tumors: predictive value in comparison to histopathological parameters].
Casper F; Weikel W; Schaffrath M; Kuner RP; Hoffmann G; Pollow B; Pollow K
Zentralbl Gynakol; 2000; 122(3):153-9. PubMed ID: 10756599
[TBL] [Abstract][Full Text] [Related]
14. Transformation in recurrent ovarian granulosa cell tumors: Ki67 (MIB-1) and p53 immunohistochemistry demonstrates a possible molecular basis for the poor histopathologic prediction of clinical behavior.
Costa MJ; Walls J; Ames P; Roth LM
Hum Pathol; 1996 Mar; 27(3):274-81. PubMed ID: 8600043
[TBL] [Abstract][Full Text] [Related]
15. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
16. Expression of p53 protein and Ki-67 reactivity in ovarian neoplasms. Correlation with histopathology.
Harlozińska A; Bar JK; Sedlaczek P; Gerber J
Am J Clin Pathol; 1996 Mar; 105(3):334-40. PubMed ID: 8602615
[TBL] [Abstract][Full Text] [Related]
17. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
18. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas.
Bilyk OO; Pande NT; Buchynska LG
Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468
[TBL] [Abstract][Full Text] [Related]
19. Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer.
Hengstler JG; Tanner B; Möller L; Meinert R; Kaina B
Int J Cancer; 1999 Aug; 84(4):388-95. PubMed ID: 10404091
[TBL] [Abstract][Full Text] [Related]
20. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.
Diebold J; Baretton G; Felchner M; Meier W; Dopfer K; Schmidt M; Löhrs U
Am J Clin Pathol; 1996 Mar; 105(3):341-9. PubMed ID: 8602616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
